Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer.

ABSTRACT:

Background

Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC at our academic institution.

Methods

In this single institution retrospective analysis, we assessed characteristics and survival rates of unresectable and/or metastatic pancreatic PDAC patients who started a systemic treatment between 01/2015 and 12/2021. Survival analyses were performed by Kaplan-Meier and Cox proportional hazards model.

Results

The number of 285 patients received at least two lines of treatment, but only 137 patients were suitable for third-line treatment. Subgroup

SUBMITTER: Fan M 

PROVIDER: S-EPMC10785544 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature